secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hemab Therapeutics Holdings, Inc. (COAG)
CIK:        0002114044
Form:       8-K
Filed at:   2026-08-11T11:11:07+00:00
Accession:  0001193125-26-343421
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hemab Q2 net loss $24.2M; FDA clears sutacimig Phase 3 in Glanzmann thrombasthenia
--------------------------------------------------------------------------------

- Net loss $24.2M ($0.80/share) vs $12.2M ($12.91/share) YoY; cash $457.5M, runway into 2029.
- FDA endorsed sutacimig data package for Phase 3 pivotal trial in GT; initiation planned 2H 2026.
- HMB-002 proof-of-mechanism: ≥2.4-fold VWF/FVIII increase; 8/9 patients zero treated bleeds post-dose.
- Unveiled HMB-003, novel peptide plasmin inhibitor for heavy menstrual bleeding; FIH trials 2H 2026.
- R&D expense $20.3M vs $12.9M; G&A $5.7M vs $3.2M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2114044/000119312526343421/0001193125-26-343421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2114044/000119312526343421/d180684d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer